Ms Michele Binder
BSc (Hons), MSc (Hons)

Parkville Campus
30 Royal Parade
Parkville Victoria 3052

Research group
Multiple Sclerosis and Myelin Repair Group

Michele Binder


Michele’s research is at the forefront of TAM receptor biology, with a particular focus on the role of Mertk and its sister receptor Tyro3 on myelination and glial cell biology. CI Binder’s publication describing the effect of GAS6 deletion upon demyelinating disease (Binder et al. 2008), pioneered a new avenue of research leading to the confirmation that GAS6 is an excellent candidate therapy for MS.

Recent work in our laboratory has shown that variants within the gene for the Mertk receptor are associated both with the level of expression of Mertk and with susceptibility to multiple sclerosis. Given the central role of microglia in regulating the phenotype of multiple sclerosis, I have an emerging interest in the epigenetic control of microglial phenotype in health and disease, with a particular focus on miRNA

Career highlights

Current roles

  • Group Head at The Florey

Past roles

  • Research fellow at the MRC Laboratory for Molecular Cell Biology (University Colledge London)

Awards and achievements

  • 2023 — Bethlehem Griffiths Research Foundation – Uncovering regulators of brain immune cell function that promote the healing of brain tissue
  • 2022 — Trish Multiple Sclerosis Research Foundation- Advancing tolerogenic dendritic cell therapy for multiple sclerosis toward clinical translation
  • 2022 — Multiple Sclerosis Research Australia- Development and optimisation of a human pre-clinical model of demyelination and repair
  • 2021 — Multiple Sclerosis Research Australia – Novel radioligands for PET imaging of multiple sclerosis diagnosis
  • 2020 — Perpetual Trustees – How are the brain’s immune cells regulated?
  • 2020 — Multiple Sclerosis Research Australia – Dendritic cell therapy for multiple sclerosis
  • 2020 — Bethlehem Griffiths Research Foundation – Developing dendritic cell therapy for MS based on promoting Mertk signalling
  • 2019 — National Multiple Sclerosis Society – Investigating a microglial receptor tyrosine kinase as a therapeutic target for myelin repair
  • 2019 — National Multiple Sclerosis Society (USA) – Pegylated Gas6 for treating progressive multiple sclerosis (MS)
  • 2018 — Bethlehem Griffiths Research Foundation – Sex-specific differences in microglia as a basis for individualised treatment in MS

Research publications


Please enter your first name
Please enter your last name
Please enter a valid phone number
Please enter a correct email address
Please provide information regarding your enquiry